You are here

  • Home
  • Archive
  • Volume 82, Issue Suppl 1
  • AB0199 THE PROGNOSTIC VALUE OF IGA ANTI-CITRULLINATED PROTEIN ANTIBODY AND RHEUMATOID FACTOR IN AN EARLY ARTHRITIS COHORT WITH A TREAT-TO-TARGET APPROACH

Article info

Article menu

Download PDFPDF

Scientific Abstracts
Publication only
Rheumatoid arthritis - prognosis, predictors and outcome
AB0199 THE PROGNOSTIC VALUE OF IGA ANTI-CITRULLINATED PROTEIN ANTIBODY AND RHEUMATOID FACTOR IN AN EARLY ARTHRITIS COHORT WITH A TREAT-TO-TARGET APPROACH
Free

Authors

Citation

Heutz J, Schreurs MW, Van der Helm – van Mil A, et al
AB0199 THE PROGNOSTIC VALUE OF IGA ANTI-CITRULLINATED PROTEIN ANTIBODY AND RHEUMATOID FACTOR IN AN EARLY ARTHRITIS COHORT WITH A TREAT-TO-TARGET APPROACH
Annals of the Rheumatic Diseases 2023;82:1282-1283.

Publication history

  • First published May 30, 2023.
Online issue publication 
August 17, 2023

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.